What's in Amsterdam UMC, location VUmc's pipeline?

Amsterdam UMC, location VUmc has 37 drugs in our index: 16 marketed, 0 filed, 3 in Phase 3, 5 in Phase 2, 13 in Phase 1.

Which companies overlap with Amsterdam UMC, location VUmc's portfolio?

Top competitors by shared drug class: Weill Medical College of Cornell University, Brigham and Women's Hospital, Pfizer, University of Pennsylvania, Astellas Pharma Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/amsterdam-umc-location-vumc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Amsterdam UMC, location VUmc — Portfolio Competitive Intelligence Brief

Amsterdam UMC, location VUmc pipeline: 16 marketed, 0 filed, 3 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

16 marketed 0 filed 3 Phase 3 5 Phase 2 13 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Placebo (for rivastigmine)	Placebo (for rivastigmine)	marketed			Neurology
Discontinuation of imipenem-cilastatin or meropenem	Discontinuation of imipenem-cilastatin or meropenem	marketed
ertugliflozine	ertugliflozine	marketed			Other
Ferricarboxymaltose	Ferricarboxymaltose	marketed			Other
Lopinavir/ritonavir + zidovudine + lamivudine	Lopinavir/ritonavir + zidovudine + lamivudine	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase	Infectious Disease / Virology
Change in daily dosage of Growth Hormone	Change in daily dosage of Growth Hormone	marketed	Growth hormone replacement therapy	Growth hormone receptor (GHR)	Endocrinology
Magnesium hydroxide 724mg	Magnesium hydroxide 724mg	marketed
GnRHa	GnRHa	marketed
Lopinavir/ritonavir + nevirapine	Lopinavir/ritonavir + nevirapine	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase	Infectious Disease / Virology
Macrogol Only Product in Oral Dose Form	Macrogol Only Product in Oral Dose Form	marketed	Osmotic laxative		Gastroenterology
Standard interval dosing	Standard interval dosing	marketed
Psyllium Orange	Psyllium Orange	marketed	Bulk-forming laxative / dietary fiber supplement		Gastroenterology

Therapeutic area mix

Other · 5
Oncology · 5
Infectious Disease / Virology · 2
Neurology · 2
Gastroenterology · 2
Diabetes · 1
Ophthalmology · 1
Endocrinology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Weill Medical College of Cornell University · 2 shared drug classes
Brigham and Women's Hospital · 2 shared drug classes
Pfizer · 2 shared drug classes
University of Pennsylvania · 2 shared drug classes
Astellas Pharma Inc · 1 shared drug class
AstraZeneca · 1 shared drug class
Aboca Spa Societa' Agricola · 1 shared drug class
Assistance Publique Hopitaux De Marseille · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Amsterdam UMC, location VUmc:

Cite this brief

Drug Landscape (2026). Amsterdam UMC, location VUmc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amsterdam-umc-location-vumc. Accessed 2026-05-16.